Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
暂无分享,去创建一个
P Boesiger | D Meier | A Weindl | R P Maguire | R. P. Maguire | P. Boesiger | D. Meier | A. Weindl | K. Leenders | A. Antonini | R. Maguire | P. Vontobel | R. Sánchez-Pernaute | R. Spiegel | K L Leenders | A Antonini | R Sanchez-Pernaute | P Vontobel | R Spiegel | M Weigell-Weber | J G de Yébenez | M. Weigell-Weber | J. D. de Yébenez | J. D. Yebenez
[1] H. Herzog,et al. Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.
[2] P. Hartvig,et al. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C‐N‐methyl‐spiperone , 1987, Acta neurologica Scandinavica.
[3] J. Penney,et al. Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[4] T. Högberg,et al. Synthesis of [methoxy-3H]- and [methoxy-11C]- labelled raclopride. Specific dopamine-D2 receptor ligands , 1987 .
[5] J C Mazziotta,et al. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. , 1992, Archives of neurology.
[6] J. Brandt,et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at‐risk persons , 1994, Neurology.
[7] M. MacDonald,et al. Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals , 1995, Annals of neurology.
[8] J. Jankovic,et al. CAG repeat size and clinical presentation in Huntington's disease , 1994, Neurology.
[9] R. Hichwa,et al. Normal caudate glucose metabolism in persons at risk for Huntington's disease. , 1987, Archives of neurology.
[10] E. G. Tortosa,et al. Huntington's disease: a multidisciplinary study , 1995, European journal of neurology.
[11] G. van Ommen,et al. Presymptomatic, prenatal, and exclusion testing for Huntington disease using seven closely linked DNA markers. , 1991, American journal of medical genetics.
[12] G. Sedvall,et al. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.
[13] J. Penney,et al. Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.
[14] M. Hayden,et al. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease , 1987, Neurology.
[15] C D Marsden,et al. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography , 1986, Movement disorders : official journal of the Movement Disorder Society.
[16] J. Missimer,et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. , 1995, Archives of neurology.
[17] Scott T. Grafton,et al. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease , 1990, Annals of neurology.
[18] O. Riess,et al. Improved PCR conditions for the stretch of (CAG)n repeats causing Huntington's disease. , 1993, Human molecular genetics.
[19] J. Mazziotta,et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.
[20] Shirley A. Miller,et al. A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.
[21] S. Fahn,et al. Huntington disease , 1979, Neurology.
[22] H Toyama,et al. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] P. Boesiger,et al. T2 relaxation time in patients with Parkinson's disease , 1993, Neurology.
[24] E. Spokes,et al. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. , 1980, Brain : a journal of neurology.
[25] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[26] G. Dobben,et al. Bicaudate index in computerized tomography of Huntington disease and cerebral atrophy. , 1979, Neurology.
[27] Ethical issues policy statement on Huntington's disease molecular genetics predictive test , 1989, Journal of the Neurological Sciences.
[28] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[29] S. Folstein,et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. , 1990, The Journal of neuropsychiatry and clinical neurosciences.
[30] Ira Shoulson,et al. Huntington's disease in Venezuela , 1986, Neurology.
[31] S. Folstein,et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease , 1992, Annals of neurology.
[32] E. Hirsch,et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form , 1995, Nature Genetics.
[33] G. Dobben,et al. Bicaudate index in computerized tomography of Huntington disease and cerebral atrophy , 1978, Neurology.
[34] D. Brooks,et al. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. , 1995, Brain : a journal of neurology.
[35] K. Leenders,et al. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. , 1993, Archives of neurology.